Key terms
About IKNA
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IKNA news
Mar 19
6:27am ET
Ikena Oncology’s IK-595: A Promising Contender in the MAPK-Driven Tumor Space
Mar 12
6:05pm ET
Ikena Oncology’s Promising Drug Pipeline Merits a Buy Rating
Mar 12
10:55am ET
Ikena Oncology’s IK-930: A Promising Contender in Targeted Oncology Treatments
Mar 12
8:07am ET
iKena Oncology expects cash to meet operating requirements into 2H26
Mar 12
8:06am ET
iKena Oncology reports Q4 EPS (41c), consensus (43c)
Feb 21
4:52pm ET
iKena Oncology CMO Sergio Santillana resigns, Caroline Germa succeeds
Feb 21
4:49pm ET
Ikena Oncology Announces Leadership Change and Strategic Shift
Jan 22
2:24pm ET
Ikena Oncology (IKNA) Gets a Buy from Wedbush
Jan 22
1:46pm ET
Buy Rating on Ikena Oncology: Undervalued Assets and Promising Pipeline in Oncology Sector
Jan 18
4:35pm ET
Ikena Oncology Inc trading resumes
Jan 18
4:21pm ET
iKena cuts 35% of workforce to focus on IK-930 and IK-595, to extend runway
Jan 18
4:00pm ET
Ikena Oncology Inc trading halted, news pending
No recent news articles are available for IKNA
No recent press releases are available for IKNA
IKNA Financials
Key terms
Ad Feedback
IKNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IKNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range